Evolution of the Average Target: Sanofi

Data source: Sanofi(SAN)

Evolution of the Target Price: Sanofi

Data source: Sanofi(SAN)

Changes in Analyst Recommendations: Sanofi

Data source: Sanofi(SAN)
7bdaa6.xZYVgm6-s4_5JUrTesmR0eM3PTMEo1gv9cLtgUlLNfg.ga53-COL1b-IZyenHY_yqdZAWVdCwjVrhK-07AEyRomD5ErtL8fHzMkRfg~a98d7039f278f8fa4b6dce0853e1ec1a
09-17 Sanofi : UBS reiterates its Neutral rating ZD
09-15 Sanofi : Deutsche Bank reiterates its Buy rating ZD
09-14 Sanofi : Deutsche Bank reiterates its Buy rating ZD
09-09 RBC Capital Markets Begins Sanofi's Coverage at Sector Perform MT
09-09 RBC Initiates Sanofi at Sector Perform With EUR80 Price Target MT
09-09 RBC Launches Sanofi Coverage at Sector Perform Amid Management Turnaround, 'Light' Near-term Catalysts MT
09-08 Sanofi : From a Buy to Neutral rating by RBC ZD
09-08 Sanofi : Barclays is Neutral ZD
09-02 Sanofi : Gets a Buy rating from Deutsche Bank ZD
09-01 Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says MT
08-25 Sanofi : Deutsche Bank reiterates its Buy rating ZD
08-24 Sanofi : Berenberg gives a Buy rating ZD
08-24 Berenberg Keeps Sanofi at Buy Ahead of Asthma Drug Phase 2b Trial Results MT
08-24 Berenberg Still Rates Sanofi a Buy Zonebourse
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-19 Sanofi : Deutsche Bank reiterates its Buy rating ZD
08-19 Sanofi : UBS reiterates its Neutral rating ZD
08-14 AlphaValue still cautious about Sanofi Zonebourse
08-13 Sanofi: Q2 beat gets sidelined by burning pipeline issues Alphavalue
08-10 Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says MT
08-10 Bernstein Expects Novo Nordisk to Continue Facing US GLP-1 Share Loss, Margin Pressure MT
08-07 Sanofi : Gets a Buy rating from Jefferies ZD
08-04 SANOFI : Bernstein remains its Buy rating ZD
08-03 Sanofi's rebound continues, helped by Berenberg Zonebourse
08-03 SANOFI : Berenberg reiterates its Buy rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+12.14%
+2.67%
+5.09%
+3.29%
+6.25%
- +28.98%
-4.14%
+5.99%
+21.56%
Average +9.09%
Weighted average by Cap. +8.56%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
71.79EUR
Average target price
94.06EUR
Spread / Average Target
+31.02%
High Price Target
112.00EUR
Spread / Highest target
+56.01%
Low Price Target
78.00EUR
Spread / Lowest Target
+8.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
A